Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production

Venetoclax, a Bcl-2 inhibitor, in combination with the hypomethylating agent azacytidine, achieves complete remission with or without count recovery in ∼70% of treatment-naive elderly patients unfit for conventional intensive chemotherapy. However, the mechanism of action of this drug combination is...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood
Hoofdauteurs: Lee, Jong Bok, Khan, Dilshad H., Hurren, Rose, Xu, Mingjing, Na, Yoosu, Kang, Hyeonjeong, Mirali, Sara, Wang, Xiaoming, Gronda, Marcela, Jitkova, Yulia, MacLean, Neil, Arruda, Andrea, Alaniz, Zoe, Konopleva, Marina Y., Andreeff, Michael, Minden, Mark D., Zhang, Li, Schimmer, Aaron D.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2021
Onderwerpen:
Immunobiology and Immunotherapy
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8310428/
https://ncbi.nlm.nih.gov/pubmed/34292323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020009081
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items